Abiopharma

🔍 Dalton John Merritt (Executive)

Company: Nakamoto Inc. (NAKA)

Report Date: 2026-08-27

Detailed Transactions and Holdings:

• Sold 42,492 shares of Common Stock (Direct)
  Date: 2026-08-27 | Code: A | equity_swap_involved: 0 | shares_owned_after: 81,862.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Reflects restricted stock units ("RSUs") that shall time-vest over a 2-year period starting on December 8, 2026, with no vesting during the first twelve (12) months following December 8, 2026 (the "Cliff Period"), and thereafter fifty percent (50%) of the award shall vest upon completion of the Cliff Period, with the remaining fifty percent (50%) vesting in equal quarterly installments over the subsequent twelve (12) months, subject to the Reporting Person's continued employment or service with Nakamoto Inc. (the "Issuer") through each applicable vesting date.
• F2: Effective May 22, 2026, the Issuer effected a 1-for-40 reverse stock split of the Issuer's common stock, par value $0.001 per share. The number of securities reported herein has been adjusted to reflect the reverse stock split.